These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30386103)

  • 21. Histopathology of hepatocellular carcinoma.
    Paradis V
    Recent Results Cancer Res; 2013; 190():21-32. PubMed ID: 22941011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
    Ma C; Zhang Q; Greten TF
    FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.
    Castven D; Fischer M; Becker D; Heinrich S; Andersen JB; Strand D; Sprinzl MF; Strand S; Czauderna C; Heilmann-Heimbach S; Roessler S; Weinmann A; Wörns MA; Thorgeirsson SS; Galle PR; Matter MS; Lang H; Marquardt JU
    Oncotarget; 2017 Jul; 8(30):48688-48700. PubMed ID: 28415775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.
    Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H
    BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polyploidy spectrum: a new marker in HCC classification.
    Bou-Nader M; Caruso S; Donne R; Celton-Morizur S; Calderaro J; Gentric G; Cadoux M; L'Hermitte A; Klein C; Guilbert T; Albuquerque M; Couchy G; Paradis V; Couty JP; Zucman-Rossi J; Desdouets C
    Gut; 2020 Feb; 69(2):355-364. PubMed ID: 30979717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness.
    Tsujikawa H; Masugi Y; Yamazaki K; Itano O; Kitagawa Y; Sakamoto M
    Hum Pathol; 2016 Apr; 50():24-33. PubMed ID: 26997435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular targets for prevention of hepatocellular carcinoma.
    Blum HE
    Dig Dis; 2002; 20(1):81-90. PubMed ID: 12145424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
    O'Rourke JM; Sagar VM; Shah T; Shetty S
    World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and histological correlations in liver cancer.
    Calderaro J; Ziol M; Paradis V; Zucman-Rossi J
    J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathological classification of hepatocellular carcinoma.
    Roncalli M; Park YN; Di Tommaso L
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S228-34. PubMed ID: 20547308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
    García-Vilas JA; Medina MÁ
    World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication.
    Nishida N; Kudo M
    Oncology; 2017; 92 Suppl 1():40-49. PubMed ID: 27764823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
    Ando S; Shibahara J; Hayashi A; Fukayama M
    Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnosis and differential diagnosis of hepatocellular carcinoma].
    Drebber U; Dienes HP
    Pathologe; 2006 Jul; 27(4):294-9. PubMed ID: 16767425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development.
    Tu T; Budzinska MA; Maczurek AE; Cheng R; Di Bartolomeo A; Warner FJ; McCaughan GW; McLennan SV; Shackel NA
    Int J Mol Sci; 2014 May; 15(6):9422-58. PubMed ID: 24871369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
    Mukaida N; Nakamoto Y
    World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.